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The T Allele of the Hepatic Lipase Promoter Variant
C2480T Is Associated With Increased Fasting Lipids and
HDL and Increased Preprandial and Postprandial LpCIII:B
European Atherosclerosis Research Study (EARS) II
Hans Jansen, Grace Chu, Christian Ehnholm, Jean Dallongeville, Viviane Nicaud, Philippa J. Talmud,
for the EARS Group
Abstract—The common C2480T transition in the hepatic lipase (HL) promoter has been shown to be associated with
lower HL activity and increased high density lipoprotein (HDL) cholesterol. We examined the frequency and lipid
associations of this HL polymorphism in 385 healthy, young (18- to 28-year-old) men whose fathers had had a
premature myocardial infarction (designated cases) and 405 age-matched controls. These individuals were participants
in the European Atherosclerosis Research Study II postprandial trial, who had been recruited from 11 European
countries in 4 regions (the Baltic; United Kingdom; and central and southern Europe). Overall, the frequency of the T
allele was 0.207 in controls and 0.244 in cases (P50.08). The T allele was associated with higher fasting plasma total
cholesterol (P,0.01), triglycerides (P,0.01), and HDL cholesterol (P,0.01). The strongest association was found with
apolipoprotein (apo) A-I concentration, which was 10% higher in individuals homozygous for the T allele compared
with those homozygous for the C allele (P,0.001). This polymorphism had no effect on the rise in plasma triglyceride
levels after a fatty meal. However, before and after the fat load was ingested, levels of particles containing both apoC-III
and apoB (LpC-III:B) were higher in carriers of the T allele, with homozygotes having 23% and 27% higher levels
preprandially and postprandially, respectively, than those homozygous for the C allele (P,0.05). Thus, our results
demonstrate that the C2480T polymorphism in the HL promoter is associated with alterations in plasma lipids and
lipoproteins and the accumulation of atherogenic LpC-III:B particles. (Arterioscler Thromb Vasc Biol.
1999;19:303-308.)
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Hepatic lipase (HL) plays a role in the metabolism ofseveral lipoproteins, thereby affecting plasma lipid lev-
els.1,2 The plasma HL activity measured after heparin injec-
tion is inversely correlated with HDL cholesterol levels3 and
postprandial lipoproteins.4 High HL activity is also associated
with the occurrence of small, dense LDL particles.5,6 Several
mechanisms may contribute to these associations. HL hydro-
lyzes phospholipids and triglycerides in LDL directly or after
transfer to HDL, thus lowering LDL size. HDL phospholipid
and triglyceride are preferred substrates for HL,7 and hydro-
lysis of phospholipid and triglyceride in HDL may induce
cholesterol (ester) efflux to the lipase-containing tissues.8–11
During this process HDL is converted to smaller particles,
which can again take up cholesterol from peripheral tis-
sues.8,12 In this way, HL is not only a determinant of HDL
cholesterol levels but also may be an important element in
reverse cholesterol transport. In humans, HL activity is also
correlated with postprandial lipid levels and may affect
chylomicron remnant clearance.4,13 Inhibition of HL activity
in rats by specific antibodies leads to impairment of chylo-
micron (remnant) clearance.14 The influence of HL on post-
prandial lipids may be direct or indirect. Hydrolysis of
chylomicron remnant phospholipids by HL leads to the
“unmasking” of apoE, thereby enhancing the binding of these
particles to apoE-binding receptors.15 In addition, HL may act
as a ligand for chylomicron remnants by binding the lipopro-
teins to receptors on the liver.16–18
Altogether, HL is an important enzyme with multiple
functions affecting the metabolism, composition, and concen-
tration of several lipoproteins. A deficiency of HL often leads
to a mild phenotype with elevation of HDL and/or an increase
in LDL concentration and buoyancy.13,19,20 In conjunction
with other hyperlipidemia-causing genes, HL deficiency in-
fluences plasma lipoprotein levels more strongly, with tri-
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glyceride enrichment of lipoprotein fractions with a d.1.006
g/mL, the presence of b-VLDL, and impaired metabolism of
postprandial triglyceride-rich lipoproteins.19 Thus, because of
the multiple effects of HL on lipoprotein metabolism, genetic
variation in HL expression may influence atherosclerotic risk.
Several variant sites have been identified in the HL gene,
but only a few lead to decreased postheparin plasma HL
activity.21–23 Recently, low HL activity was found to be
associated with a common C-to-T base substitution in the HL
promoter.24–27 This transition is at position 2480 based on
the sequence published by Cai et al28 and at position 2514
based on the sequence of Ameis and coworkers.29 The 2514
C-to-T polymorphism was recently shown to be in complete
linkage disequilibrium with 3 other polymorphisms in the HL
promoter (2250 G to A, 2710 T to C, and 2763 A to G).30
To date no effects of any of these substitutions on HL
promoter activity in vitro have been reported. In addition to
low HL activity, the T allele was found to be associated with
an increased HDL cholesterol content in males in the Neth-
erlands, Finland, and the United States.25,31,30 In a Dutch
sample of normolipidemic men with coronary artery disease
(CAD), the frequency of the T allele was higher than in
nonsymptomatic controls.25 In contrast, in a Finnish study of
subjects with a family history of myocardial infarction, the
occurrence of the T allele was the same as in healthy
subjects.31 We carried out our investigation on subjects taking
part in the European Atherosclerosis Research Study (EARS)
II, a postprandial trial of young, male, university students
from 11 European countries (L. Tiret et al, unpublished
observations, 1998) whose fathers had documented CAD
(designated as cases) and age-matched controls, thus enabling
us to examine populations of different European regions.
Moreover, because HL deficiency may result in impaired
postprandial lipoprotein metabolism,19 we studied whether
the HL polymorphism influenced the lipid response to an oral
fat load.
Methods
Subjects
Subjects were participants of EARS II, which was performed in
1993. Four hundred seven male students between the ages of 18 and
28 years whose fathers had proven myocardial infarction before the
age of 55 (cases) were recruited from 14 university student popula-
tions from 11 European countries. One age-matched control was
recruited by random selection from the same university populations
(n5415). Tallinn, Estonia (cases/controls, 32/36) and Helsinki
(32/33) and Oulu (23/23), Finland, were designated Baltic; Glasgow
(31/31), Belfast (33/33), and Bristol (22/23) were designated United
Kingdom; Aarhus, Denmark (30/30), Hamburg, Germany (32/32),
Ghent, Belgium (32/32), and Zurich, Switzerland (36/36), were
designated central Europe; and Lisbon, Portugal (18/18), Reus, Spain
(30/33), Naples, Italy (30/30), and Athens, Greece (26/25), were
designated southern Europe. The subjects were presumed to have
been born in the country where they were studying. Details of
lifestyle, smoking habits, alcohol consumption, medication, physical
exercise, a personal and family history, and physiological measure-
ments, were established using standardized questionnaires and pro-
tocols (Table 1).
Postprandial Tests
At the first visit each participant underwent a standard 75-g oral
glucose tolerance test (OGTT) after a 12-hour overnight fast. Venous
blood was withdrawn at 0, 30, 60, 90, and 120 minutes for the
determination of glucose and insulin concentrations.
One week later the oral fat tolerance test was performed. The
standard meal had an energy content of 1493 kcal (6186 kJ)
consisting of 21.6 g protein, 65.5 g fat (of which 41.64 g was
saturated), 56.2 g carbohydrate, and 416.6 mg cholesterol. The drink
was made from 1 can of cream (Nestle´ double cream), sugar
(sucrose), and milk protein (Marvel). Blood samples were withdrawn
at 0, 2, 3, 4, and 6 hours for the determination of triglyceride
concentration. Levels of particles containing apoC-III and apoB
(LpC-III:B) were measured at 0 and 4 hours.
Lipid and Lipoprotein Particle Measures
All fasting lipids and apolipoproteins were measured at baseline of
the OGTT, and fasting triglycerides, insulin, and glucose were
remeasured at baseline of the OGTT. LpC-III:B’s were measured by
a noncompetitive (sandwich) ELISA as described previously.32 In
brief, polystyrene microtiter plates were coated with affinity-purified
polyclonal antibodies to human apoC-III (1 mg/mL). Duplicate
plasma samples were diluted 1:1000, 1:2000, and 1:5000 with
100 mmol/L PBS containing 1% albumin. The samples were added
to the wells along with the standards and controls and incubated for
2 hours at 37°C. After incubation, the plates were washed 4 times
with PBS, and a rabbit polyclonal apoB antibody conjugated to
peroxidase was added. The plates were incubated for 2 hours at 37°C
and then washed. Color development was performed for 30 minutes
by addition of a peroxidase substrate (o-phenylenediamine dichlo-
ride, Sigma Chemical Co). The plates were read at 492 nm on an
automated microplate reader model EL340 (Bio-Tek Instruments). A
pool of 400 different plasma samples was used as a secondary
standard. This pool was calibrated using immunopurified LpC-III:B.
The apoB concentration of the particles was determined by nephe-
lometry using the BNA system and apoB standards (Behringwerke).
The values are expressed as the amount of apoB associated with
apoC-III.
DNA Extraction and Genotyping
DNA was extracted by the salting-out method.33 The DNA was
stored diluted in 96-well Beckman plates,34 divided into aliquots into
96-well Omnigene plates, and dried. The polymerase chain reaction
(PCR) mixture consisted of 50 mmol/L KCl, 10 mmol/L Tris (pH
8.3), 0.1 g/L gelatin (Sigma), 0.2 mmol/L of each dNTP, 1.5 mmol/L
MgCl2, 0.02% W-1 (GIBCO), 0.1 U of Taq polymerase (Gibco
BRL)/10 mL PCR, and 0.2 nmol/L of each of the PCR primers
described by Jansen et al25 for the C2480T variant.
TABLE 1. Anthropometric and Lifestyle Characteristics in
Cases and Controls
Cases
(n5385)
Controls
(n5405) P
Age, y 22.8 (0.1) 22.8 (0.1) NS
Alcohol consumption, mL/d 20.1 (1.1) 18.0 (1.0) NS
Smokers, % 26.6 (2.3) 25.0 (2.2) NS
Physical activity, %
Minimal 10.2 (1.6) 8.2 (1.4) NS
Moderate 75.3 (2.2) 76.4 (2.1) NS
Heavy 14.5 (1.8) 15.4 (1.8) NS
Body mass index, kg/m2 23.4 (0.1) 23.3 (0.1) NS
Waist-hip ratio 0.849 (0.002) 0.851 (0.002) NS
Triglycerides, mmol/L 1.00 (0.02) 0.96 (0.02) NS
Total cholesterol, mmol/L 4.54 (0.04) 4.30 (0.04) ,0.001
HDL cholesterol, mmol/L 1.19 (0.01) 1.19 (0.01) NS
LDL cholesterol, mmol/L 2.90 (0.04) 2.69 (0.04) ,0.001
ApoA-I, mg/dL 99.9 (0.9) 100.3 (0.8) NS
ApoB, mg/dL 73.6 (0.9) 69.1 (0.8) ,0.001
ApoE, mg/dL 2.90 (0.04) 2.78 (0.04) NS
Values are mean and (SD).
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The PCR products were subjected to restriction enzyme analysis
by digestion with 2 U of the restriction endonuclease NlaIII (NEB)
per 7 mL of the PCR sample at 37°C for 4 hours and in the buffer
recommended by the manufacturer. The samples were then loaded
on to an ethidium bromide–prestained microplate array diagonal gel
electrophoresis gel as described,34 electrophoresed for 1 hour and 20
minutes, and marked for the genotypes.
Statistical Analysis
The data were analyzed using the SAS statistical software package
(SAS Institute Inc). Observed numbers of each genotype were
compared with those expected for Hardy-Weinberg equilibrium in
cases and controls from the 4 regions by using the x2 test. Allele
frequencies were compared between cases and controls by the
Mantel-Haenszel test after adjustment for region. Statistical signifi-
cance for this and all other tests was taken to be P,0.05. Triglyc-
erides and LpC-III:B were logarithmically transformed before the
tests to remove positive skewness. For postprandial analyses of
triglycerides, 2 parameters were calculated: the area under the curve
(AUC, in mmol-h/L) above the fasting concentration, calculated by
the trapezoidal rule, and the peak (mmol/L), calculated as the highest
value minus the fasting value. The C2480T genotype was tested
after assuming additive effects of alleles in a codominant model. For
lipid analysis, data for cases and controls were pooled because no
significant interaction between case/control status and the HL 2480
variant could be detected. The means were adjusted for status, age,
and center.
Results
Study Population
The study population consisted of 790 subjects, of whom 385
were cases and 405 were controls. The cases and controls did
not significantly differ in anthropometric or lifestyle charac-
teristics. Total cholesterol, LDL cholesterol, and apoB were
higher in cases than in controls (Table 1). The presence of the
C2480T polymorphism was determined in all subjects.
Overall, the frequency of the 2480T allele was 0.207 in
controls and 0.244 in cases (P50.08). The allele frequencies
were in Hardy-Weinberg equilibrium in all 4 regions and are
presented in Table 2.
Relation to Plasma Lipids, Lipoproteins,
and Apolipoproteins
The association of the rare 2480T allele with plasma lipid
and lipoprotein levels in cases and controls is shown in Table
3. There was no significant interaction between case/control
status and genotype, so cases and controls were pooled to
acquire sufficient numbers for T/T carriers. In the pooled
data, the 2480T allele was associated with higher fasting
plasma total cholesterol, triglyceride, and HDL cholesterol.
These results conform to a codominant model, because the
homozygous T/T carriers had the highest values followed by
the C/T carriers, and the lowest values were found in the C/C
homozygotes. LDL cholesterol did not differ among the
different genotypes. Although in carriers of the T allele both
plasma triglyceride and HDL were increased, the inverse
correlation between fasting triglyceride level and HDL cho-
lesterol concentration was significantly stronger in the
2480T homozygotes than in heterozygotes or 2480C ho-
mozygotes (correlation coefficients of 20.65, 20.26, and
20.32, respectively; P,0.05). The strongest association of
the C2480T polymorphism was with apoA-I. In T/T carriers
the apoA-I concentration was 10% higher than in 2480C/C
homozygotes (P,0.001). ApoB was slightly higher in T
allele carriers than in C/C homozygotes, but there was no
TABLE 2. Genotype and Allele Frequencies of the C2480T
Polymorphism of the HL Gene
No.
T Allele
Carriers, %
T Allele
Frequency
All
Cases 385 43.6 0.244
Controls 405 38.0 0.207
Baltic states
Cases 85 45.9 0.241
Controls 90 47.8 0.261
UK
Cases 76 40.8 0.237
Controls 85 35.3 0.200
Central Europe
Cases 122 46.7 0.266
Controls 125 40.0 0.212
Southern Europe
Cases 102 40.2 0.226
Controls 105 29.5 0.162
TABLE 3. Plasma Lipids and Apolipoproteins According to the
C2480T HL Promoter Polymorphism
Genotype
Test*CC CT TT
Cases:controls 217:251 148:140 20:14
Triglyceride,
mmol/L
Cases 0.99 (0.03) 1.02 (0.04) 1.02 (0.10) ,0.05
Controls 0.93 (0.03) 0.99 (0.04) 1.13 (0.11)
Cholesterol,
mmol/L
Cases 4.47 (0.06) 4.62 (0.07) 4.56 (0.18) ,0.01
Controls 4.23 (0.05) 4.40 (0.07) 4.88 (0.22)
LDL cholesterol,
mmol/L
Cases 2.88 (0.05) 2.96 (0.06) 2.84 (0.16) NS
Controls 2.65 (0.05) 2.73 (0.06) 2.89 (0.20)
HDL cholesterol,
mmol/L
Cases 1.16 (0.02) 1.21 (0.02) 1.27 (0.05) 0.01
Controls 1.16 (0.02) 1.22 (0.02) 1.25 (0.08)
ApoA-I, mg/dL
Cases 97.9 (1.1) 101.8 (1.4) 108.1 (3.8) ,0.001
Controls 98.0 (1.1) 103.6 (1.4) 108.5 (4.5)
ApoB, mg/dL
Cases 72.5 (1.1) 75.5 (1.4) 71.8 (3.7) ,0.05
Controls 67.8 (1.1) 70.8 (1.4) 74.8 (4.4)
ApoE, mg/dL
Cases 2.87 (0.06) 2.92 (0.07) 3.04 (0.19) NS
Controls 2.74 (0.05) 2.82 (0.07) 3.11 (0.22)
*The P values refer to the levels of significance in the different variables after
pooling the data for cases and controls.
Jansen et al February 1999 305
difference between the C/T and T/T genotypes. There was no
genotype effect on body mass index, waist-hip ratio, or
plasma glucose or insulin concentrations.
Postprandial Triglyceride and LpC-III:B Response
Because HL is involved in postprandial lipid clearance, we
studied the effects of the C2480T polymorphism on post-
prandial triglyceride concentrations after a fat tolerance test
(Figure 1). There were no significant differences in the mean
triglyceride concentrations between the different genotypes
when tested either directly or after adjustment for fasting
triglyceride. Differences in the AUC, peak height minus
fasting concentration, or the time at which the triglyceride
value reached its peak did not reached statistical significance
among genotypes (Table 4). The association of the poly-
morphism with the concentration of LpC-III:B was also
studied before and after the fat load. Before the fat load, the
concentration of LpC-III:B was dose-dependently higher in
the 2480T allele carriers than in noncarriers. Homozygous T
allele carriers had a 23% higher value than did individuals
homozygous for the 2480C allele (P,0.05; Figure 2). After
the fat load this difference in LpC-III:B concentration re-
mained, with 2480T homozygotes having the highest levels
of LpC-III:B (P,0.05).
Discussion
We determined the frequency of the T allele of the HL gene
promoter polymorphism, referred to as C2480T24 or 2514C/
T,30 and lipid associations in young, healthy men whose
fathers had had a premature myocardial infarction (cases) and
in age-matched controls (EARS II; L. Tiret et al, unpublished
observations, 1998). Overall, the allele frequencies found
were in the same range ('0.2) as those previously reported in
the Netherlands, Finland, and the United States.25,30,31 The
study population consisted of university students recruited in
northern (the Baltic), central, and southern Europe and the
United Kingdom. When all 4 regions were pooled, no
significant difference in the frequency of the T allele between
cases and controls was found (P50.08). The T allele was
associated with an increased concentration in plasma triglyc-
eride, total cholesterol, HDL cholesterol, apoA-I, and apoB.
Whether or to what extend the changes in plasma lipids are
related to atherosclerosis is not clear. On the one hand, HDL
cholesterol and apoA-I were increased in T allele carriers,
suggesting that the T allele may be associated with a reduced
atherogenic risk. On the other hand, the T allele was also
associated with higher plasma triglyceride and cholesterol.
Moreover, in carriers of the T allele, the concentration of
LpC-III:B was significantly increased both preprandially and
postprandially. ApoC-III is an important determinant of
triglyceride-rich lipoprotein clearance. In vitro studies have
shown that apoC-III inhibits lipoprotein lipase35 and HL
activities36 and displaces apoE from the surface of triglycer-
ide-rich lipoproteins. Therefore, in metabolic conditions in
which lipolytic activity is decreased, lipoprotein particles that
are enriched in apoC-III tend to accumulate. LpC-III:B is
associated with CAD.37–40 Thus overall, the T allele is
Figure 1. Postprandial changes in plasma triglyceride concen-
tration after the fat tolerance test according to C2480T poly-
morphism. Mean plasma triglyceride concentrations 6SD are
given. -1- indicates CC genotype; -E-, CT genotype; and --,
TT genotype. Values are adjusted for age, center, and case/con-
trol status. All associations were not significant, whether tested
as 3 codominant classes or T1 versus CC. There were no sig-
nificant interactions with status, body mass index, waist-hip
ratio, or fasting triglyceride level.
TABLE 4. Plasma Triglyceride Concentration and LpC-II:B
After the Fat Tolerance Test According to C2480T Genotype
Genotype
P*CC CT TT
Cases:controls 207:237 137:129 17:14
AUC† 3.82 (0.11) 3.99 (0.14) 3.71 (0.41) NS
Peak height
minus fasting
value†
1.20 (0.03) 1.25 (0.04) 1.20 (0.12) NS
Time to peak‡ 2.91 (0.04) 2.92 (0.05) 2.52 (0.16) NS
Cases:controls 184:211 129:115 18:14
LpC-III:B, g/L
0 Hour 0.096 (0.003) 0.102 (0.004) 0.118 (0.011) ,0.05
4 Hours 0.101 (0.004) 0.110 (0.005) 0.127 (0.014) ,0.05
*The P values refer to the levels of significance in the different variables after
pooling the data for cases and controls.
†Test performed on square-root values.
‡Wilcoxon rank-sum test.
Figure 2. LpC-III:B concentrations according to C2480T poly-
morphism. LpCIII:B concentrations in different genotypes were
measured before and 4 hours after an oral fat load. Open bars
indicate C/C genotype (n5395); hatched bars, C/T genotype
(n5244); and solid bars, T/T genotype (n532). Values are means
adjusted for age, center, and case/control status. C2480T was
tested after assuming codominance. The test was performed on
logarithmically transformed values. There were no significant
interactions with status, body mass index, or waist-hip ratio.
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associated with a number of potentially antiatherogenic and
proatherogenic lipoprotein changes in our population. In a
population of normolipidemic men with CAD25 and in white
Americans,30 the T allele was also associated with enhanced
HDL, but not with total cholesterol and triglyceride. In our
population, why effects of the T allele on total cholesterol and
triglyceride were also found is not clear. Possibly, differences
in selection criteria (age, normolipidemia) between the dif-
ferent studies may play a role. Although we did not determine
HL activity in our population, the changes in plasma lipids
are presumably related to a lower HL activity in the T allele
carriers, as has been shown to exist in a number of other
populations.25–27 In which way the C2480T substitution or
other polymorphisms lead to lowered HL expression is not
known. To date, no effects of any of these substitutions on HL
promoter activity in vitro have been reported. It is interesting
to note that the C-to-T substitution at 2480 disrupts a
potential upstream stimulatory factor binding site. Upstream
stimulatory factor is an insulin-inducible transcription factor
involved in the regulation of hepatic lipid and carbohydrate
metabolism.41–43 However, whether this is related to or
causes the lowered HL activity in the T allele carriers is not
clear. Studies on this subject are in progress.
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